484 studies on Insulin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This meta-analysis provides compelling evidence that Tirzepatide, a dual GIP and GLP-1 receptor agonist, could be a valuable adjunct therapy for Type 1 Diabetes patients, offering significant improvements in glycemic …
This comprehensive review significantly advances our understanding of the multifaceted actions of GLP-1 Receptor Agonists, extending beyond their well-known direct metabolic effects. The identified interplay between G…
This comprehensive review highlights the significant potential of incretin-mimetic drugs as a strategy for cancer prevention, especially in populations at high risk due to obesity and metabolic disorders. The findings…
This review significantly advances our understanding of the multifaceted nature of obesity, providing a robust framework for developing more effective and personalized treatments. The detailed exploration of molecular…
This research highlights the potent renoprotective capabilities of multi-agonist incretin therapies, particularly Retatrutide, in managing Diabetic Kidney Disease. The superior efficacy of Retatrutide, which targets G…
This review is crucial for clinicians and researchers, underscoring the need for a paradigm shift in Type 2 Diabetes (T2D) management from a purely pharmacological approach to a holistic, integrated model. It emphasiz…
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
This comprehensive quantitative comparison provides invaluable evidence for clinicians and patients, offering clear guidance on the expected weight loss from different GLP-1 RAs. The findings underscore the varying po…
This review highlights the significant potential of triple agonists to offer a more potent and comprehensive therapeutic strategy for obesity and its associated metabolic complications. The synergistic activation of G…
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
This review critically underscores the importance of a holistic and integrated approach to weight management when utilizing powerful pharmacological tools like GLP-1 RAs. Preserving muscle mass is not merely an aesthe…
This review underscores the critical importance of understanding glucagon's pleiotropic (multiple) actions beyond glucose regulation. By elucidating shared mechanistic pathways, it provides a robust scientific rationa…
This comprehensive review highlights the significant therapeutic potential of GLP-1 agonists as a multi-faceted treatment for PCOS, addressing not only metabolic dysfunction like insulin resistance and obesity but als…
This review provides a critical roadmap for clinicians and researchers, consolidating the evidence for GLP-1 RAs as a cornerstone of modern obesity treatment. Understanding both their profound benefits and inherent li…
Repurposing glucagon represents a significant paradigm shift in the treatment of obesity and type 2 diabetes, offering a novel and powerful approach beyond current single-target therapies. By harnessing its beneficial…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
This systematic review provides compelling evidence that next-generation incretin agonists offer superior efficacy for both weight management and glycemic control in overweight and obese individuals. The substantial w…
Retatrutide's ability to simultaneously address obesity, insulin resistance, and multiple facets of MASH pathology is highly promising. This multi-target approach could offer a superior therapeutic strategy for a comp…
This comprehensive overview highlights Retatrutide's potential as a transformative therapeutic agent for managing the complex interplay of type 2 diabetes and obesity, offering a more holistic approach to metabolic he…
This groundbreaking research powerfully highlights the potential of Thymosin alpha 1 as a novel and effective therapeutic agent for addressing the complex systemic complications of cystic fibrosis, offering a much-nee…
This pilot study provides early evidence that immunomodulatory therapies like etanercept and alpha-1 antitrypsin could significantly enhance the success of autologous islet transplantation by reducing early inflammato…
This research is significant because it identifies a novel role for Ipamorelin beyond its known growth hormone-releasing effects, demonstrating its ability to directly stimulate insulin secretion. The finding that Ipa…
This study unequivocally highlights the severe public health risks associated with the use of unregulated black market growth-promoting products. Consumers are frequently exposed to mislabeled, contaminated, or entire…
This study conclusively demonstrates the efficacy of CJC-1295 as a potent, long-acting stimulator of the GH/IGF-1 axis, offering a significant advancement over traditional GHRH therapies. Its ability to provide sustai…
These findings provide a deeper understanding of the systemic effects of GH/IGF-1 axis activation beyond just GH and IGF-1 levels, revealing a complex interplay with various physiological pathways. The observed change…
This research highlights a critical, often overlooked, factor in analytical accuracy for peptide quantification, particularly in sensitive areas like doping analysis and biopharmaceutical research. The findings unders…
The ability of Sermorelin to stimulate the body's natural GH production offers a significant advantage over direct GH replacement, potentially reducing side effects and maintaining physiological feedback loops. This a…
This study is significant because it confirms the sustained efficacy and long-term safety of TH9507 (Tesamorelin) as a targeted treatment for HIV-associated lipodystrophy, a challenging side effect of ART. Reducing vi…
If the trial yielded positive results, this study would validate an oral therapeutic approach for fibromyalgia, potentially offering a more convenient and accessible alternative to injectable growth hormone. An effect…
While the detailed quantitative results from this completed clinical trial are not yet publicly available in this record, the study successfully concluded its primary objective of assessing Tirzepatide's influence on …
The premature termination of this Phase 2 study signifies that the potential of CJC 1295 as a viable treatment for HIV-associated visceral obesity remains entirely unconfirmed and unexplored through the completion of …
These findings suggest that PrP-CPP holds significant promise as a novel therapeutic strategy for Type II Diabetes by directly targeting the underlying pathology of IAPP aggregation. By preventing the formation of tox…
The systematic review consistently demonstrated that tirzepatide led to significant and dose-dependent reductions in body weight across various populations, including individuals with obesity and those with type 2 dia…
The widespread and increasing misuse of peptides poses a significant threat to the integrity of sports and the long-term health of athletes. This comprehensive review provides crucial insights for anti-doping organiza…